Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

Literature DB >> 26250577

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

Jyoti Nangalia¹, Francesca L Nice², David C Wedge³, Anna L Godfrey⁴, Jacob Grinfeld¹, Clare Thakker², Charlie E Massie², Joanna Baxter⁵, David Sewell⁵, Yvonne Silber², Peter J Campbell¹, Anthony R Green⁶.

Abstract

Entities: Chemical

Keywords: DNMT3A mutation; mutation order; myeloproliferative neoplasms

Mesh：

Substances：

Year: 2015 PMID： 26250577 PMCID： PMC4825297 DOI： 10.3324/haematol.2015.129510

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

15 in total

1. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

Authors: O Abdel-Wahab; A Pardanani; R Rampal; T L Lasho; R L Levine; A Tefferi
Journal: Leukemia Date: 2011-04-26 Impact factor: 11.528

2. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.

Authors: Isabella Fried; Claudia Bodner; Monika M Pichler; Karin Lind; Christine Beham-Schmid; Franz Quehenberger; Wolfgang R Sperr; Werner Linkesch; Heinz Sill; Albert Wölfler
Journal: Haematologica Date: 2011-10-11 Impact factor: 9.941

3. DNMT3A mutations in myeloproliferative neoplasms.

Authors: F Stegelmann; L Bullinger; R F Schlenk; P Paschka; M Griesshammer; C Blersch; S Kuhn; S Schauer; H Döhner; K Döhner
Journal: Leukemia Date: 2011-05-03 Impact factor: 11.528

4. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.

Authors: Nisha Rao; Carolyn M Butcher; Ian D Lewis; David M Ross; Junia V Melo; Hamish S Scott; Peter G Bardy; Richard J D'Andrea
Journal: Br J Haematol Date: 2011-08-22 Impact factor: 6.998

5. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

Authors: Kelly Moran-Crusio; Linsey Reavie; Alan Shih; Omar Abdel-Wahab; Delphine Ndiaye-Lobry; Camille Lobry; Maria E Figueroa; Aparna Vasanthakumar; Jay Patel; Xinyang Zhao; Fabiana Perna; Suveg Pandey; Jozef Madzo; Chunxiao Song; Qing Dai; Chuan He; Sherif Ibrahim; Miloslav Beran; Jiri Zavadil; Stephen D Nimer; Ari Melnick; Lucy A Godley; Iannis Aifantis; Ross L Levine
Journal: Cancer Cell Date: 2011-06-30 Impact factor: 31.743

6. Dnmt3a is essential for hematopoietic stem cell differentiation.

Authors: Grant A Challen; Deqiang Sun; Mira Jeong; Min Luo; Jaroslav Jelinek; Jonathan S Berg; Christoph Bock; Aparna Vasanthakumar; Hongcang Gu; Yuanxin Xi; Shoudan Liang; Yue Lu; Gretchen J Darlington; Alexander Meissner; Jean-Pierre J Issa; Lucy A Godley; Wei Li; Margaret A Goodell
Journal: Nat Genet Date: 2011-12-04 Impact factor: 38.330

7. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.

Authors: Myunggon Ko; Hozefa S Bandukwala; Jungeun An; Edward D Lamperti; Elizabeth C Thompson; Ryan Hastie; Angeliki Tsangaratou; Klaus Rajewsky; Sergei B Koralov; Anjana Rao
Journal: Proc Natl Acad Sci U S A Date: 2011-08-22 Impact factor: 11.205

8. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Authors: Robert Kralovics; Soon-Siong Teo; Sai Li; Alexandre Theocharides; Andreas S Buser; Andre Tichelli; Radek C Skoda
Journal: Blood Date: 2006-05-04 Impact factor: 22.113

Review 9. Mouse models of myeloproliferative neoplasms: JAK of all grades.

Authors: Juan Li; David G Kent; Edwin Chen; Anthony R Green
Journal: Dis Model Mech Date: 2011-05 Impact factor: 5.758

10. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors: J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal: N Engl J Med Date: 2013-12-10 Impact factor: 91.245

39 in total

Review 1. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors: Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal: Curr Hematol Malig Rep Date: 2015-12 Impact factor: 3.952

Review 2. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Authors: Zhuang Zuo; Shaoying Li; Jie Xu; M James You; Joseph D Khoury; C Cameron Yin
Journal: Curr Hematol Malig Rep Date: 2019-10 Impact factor: 3.952

Review 3. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Authors: Tariq I Mughal; Jason Gotlib; Ruben Mesa; Steffen Koschmieder; H Jean Khoury; Jorge E Cortes; Tiziano Barbui; Rüdiger Hehlmann; Michael Mauro; Susanne Saussele; Jerald P Radich; Richard A Van Etten; Giuseppe Saglio; Srdnan Verstovek; Robert Peter Gale; Omar Abdel-Wahab
Journal: Leuk Res Date: 2018-02-14 Impact factor: 3.156

DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype.

1. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

2. Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.

3. DNMT3A mutations in myeloproliferative neoplasms.

4. Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient.

5. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

6. Dnmt3a is essential for hematopoietic stem cell differentiation.

7. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.

8. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

Review 9. Mouse models of myeloproliferative neoplasms: JAK of all grades.

10. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Review 1. What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Review 2. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Review 3. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Review 4. Mutational profiling in myelofibrosis: implications for management.

Review 5. Myeloproliferative neoplasms: from origins to outcomes.

Review 6. Genetics of progression from MDS to secondary leukemia.

Review 7. Applied genomics in MPN presentation.

Review 8. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Review 9. The role of driver mutations in myeloproliferative neoplasms: insights from mouse models.

Review 10. The Molecular Genetics of Myeloproliferative Neoplasms.